Resistance to venetoclax (Venclexta ®  and Venclyxto ® , Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge,...
TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that...
RALEIGH, N.C. and TEL-AVIV, Israel , Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL ) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced...
On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued...
 Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...
The deal aims to accelerate Talicia's entry into new Middle East marketsÂ
The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill
Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts